

SUBJECT INDEX

A

A-cells

- B-cell responses and, 17
- to antigen, 14-16
- lymphokines and, 16, 22
- T-cells and, 299-301
- T-helper cells and, 167

Acceptor cells

- macrophages as, 52
- nonspecific, 51-52
- See also T-acceptor cells

Accessory cells

- See A-cells

Acetaminophen

- interleukin-2 toxicity and, 694

Acetylcholine receptors

- idiotypic mimicry of, 262

Acquired immunodeficiency syndrome

- immunologic abnormalities and, 98-99
- interleukin-2 and, 689
- lymphadenopathy-associated virus and, 97-112
- pathophysiological model of, 109-12
- populations at risk for, 98

Acquired immunodeficiency syndrome-related complex, 98

Actinomycin D

- interleukin-2 receptor and, 80-81

ADCC

- See Antibody-dependent, cell-mediated cytotoxicity

Adenocarcinoma

- cancer immunotherapy and, 705

Adenosine triphosphate

- natural killer cytotoxic factor and, 662-63
- panspecific hemopoietin and, 221

s-Adenosylhomocysteine

- methyltransferases and, 441

s-Adenosylmethionine

- methyltransferases and, 441

Adenylate cyclase

- immunoglobulin E receptor and, 445-46

Adoptive immunotherapy

- interleukin-2 and, 694-705

B-Adrenergic receptors

- idiotypic mimicry of, 260-62
- reovirus receptors and, 266-67

Agglutination

- antibodies and, 3

Agglutinins, 3-4

AIDS

- See Acquired immunodeficiency syndrome

ALL

- See Leukemias, acute lymphocytic

Allelic exclusion

- immunoglobulin genes and, 350-55, 548-49

Alloantibody

- allograft rejection and, 128

Alloantigens

- cytolytic response to interleukin-2 and, 683-85
- immunosuppressive therapy and, 683-84

Allogeneic recognition

- murine MHC class-I mutants and, 485-86

Allograft rejection, 119-40

- cellular mechanisms of, 134-40
- cytotoxic T-cells and, 122-28
- delayed-type hypersensitivity and, 122-25
- dendritic cells and, 121-22
- human studies of, 130-32
- humoral mechanisms of, 132-34
- natural killer cells and, 134
- peripheral sensitization and, 128-29
- phases of, 120

Allografts

- cytotoxic T-cells and, 125-28
- major histocompatibility antigens and, 125

Alpha factors

- B-cell responses and, 17-18

Alprenolol

- antidiotypes and, 261

Aluminum compounds

- adjuvant activity of, 370-71

Aluminum hydroxide

- complement pathway and, 371

ALV

- See Avian leukosis virus

Amino acid sequence analysis

- antidextran hybridoma proteins and, 152-54

- class-I murine MHC and, 473-80

- immunoglobulin E receptor and, 422-24

- immunoglobulin genes and, 531-32, 536-38, 624

- interleukin-2 receptor, 82
- lymphoma cells and, 623-24

- panspecific hemopoietin and, 212-13

- T-cell receptor genes and, 568-69

Ammonium chloride

- adult T-cell leukemia and, 90
- natural killer cytotoxic factor and, 662-63

Anamnestic response, 6

Anaphylactoid purpura

- immunoglobulin A and, 407

Antiazophenylarsonate antibodies

- idiotypes of, 157-59

Antibodies

- agglutination and, 3
- anti-interleukin-2 receptor adult T-cell leukemia and, 89-90
- immunosuppression and, 90-91
- antidiotypic, 255-57
- antifactor H and, 270
- autoimmune diseases and, 254, 272
- chronic lymphocytic leukemia cells and, 640
- contact sensitivity and, 58-59
- hormone receptors and, 257-60
- human autoimmune sera and, 273
- neurotransmitter receptors and, 260-62
- plasmacytoma immunoregulation and, 634
- preparation of, 263-64

- reovirus receptors and, 262-69
- retrovirus receptors and, 269-71
- vitamin receptors and, 257-60
- antiimmunoglobulin
 - B-cells and, 640-41
- antitarget
 - natural killer cells and, 654
- contact sensitivity and, 58-59
- formation of, 4-7
- radiosensitivity of, 4-5
- template theory of, 3
- hypersensitivity and, 4
- Ia and, 301-8
- idiotypes of, 151-57
- immune, 3-4, 7
- leukoagglutinating
 - allograft rejection and, 132
- lymphocytotoxic
 - allograft rejection and, 132-33
- monoclonal, 621-23
 - allograft rejection and, 135
 - anti-interleukin-2 receptor and, 70-72, 178
 - B-cell precursors and, 625-26
 - B-cell responses and, 17-23
 - class-I murine MHC and, 481-83, 489-94
 - complement component C9 and, 519
 - immunoglobulin A and, 407
 - immunoglobulin E receptor and, 429-30
 - T-cell activation and, 603-5
 - T-cell antigen receptor and, 533, 594
 - T3 chains and, 596-97
 - myeloma proteins and, 621-22
 - panspecific hemopoietin receptor and, 221
 - plasma cells and, 4
 - polyclonal
 - B-cell responses and, 17
 - specificity of, 7
 - globulins and, 3
 - synthesis of
 - antiidiotypes and, 254
 - titers
 - logarithmic rise in, 6-7
- Antibody assays
 - lymphadenopathy-associated virus and, 107
- Antibody-dependent, cell-mediated cytotoxicity
 - allograft rejection and, 128
 - immunoglobulin A and, 407-8
 - natural killer cells and, 657
- Antibody response
 - T cell-B cell collaboration in, 168-69
- Antidextran antibodies
 - idiotypes of, 151-54
- Antigalactan antibodies
 - idiotypes of, 156
- Antigen clearance
 - immunoglobulin A and, 405
- Antigen-presenting cells
 - Ia-transfectants and, 297-301
- Antigen receptors
 - idiotypes and, 254
- Antigens
 - activated lymphocytes and, 16
 - B-cell growth and, 19, 26
 - B-cell responses to, 14-16
 - cell-surface
 - B-cell precursors and, 625-26
 - delayed-type hypersensitivity and, 9
 - hepatitis B surface
 - muramyl dipeptides and, 378
 - human leukocyte, 473
 - allograft rejection and, 132-33
 - class-I variants of, 478-84
 - humoral response to, 13
 - Ia-transfectants and, 297-301
 - immunoglobulins and, 9
 - internal images of, 255
 - major histocompatibility
 - allografts and, 125
 - T-cells and, 602
 - plasmacytoma immunoregulation and, 636-37
 - reticuloendothelial system and, 16
 - T-cell factors and, 47-49
 - T-cell receptors and, 9
 - T-cells and, 566-68
 - T-helper factors and, 43-46
 - transfer factors and, 9
 - transplantation, 471
 - class-I, 472
 - myeloma protein antigens and, 633
 - T-suppressor cells and, 9, 44-45, 49-51
 - See also T-cell antigen receptor
- Antiidiotypes, 148-50
 - internal image, 256
- Antiidiotype
 - antigenic mimicry by, 256
 - antiinsulin, 258-59
 - antiretinol-binding protein, 258
 - antithyrotropin, 259-60
 - autoimmunity and, 272-74
- Antidiotype antibodies
 - antifactor H and, 270
 - autoimmune diseases and, 254, 272
 - chronic lymphocytic leukemia cells and, 640
 - contact sensitivity and, 58-59
 - hormone receptors and, 257-60
 - human autoimmune sera and, 273
 - neurotransmitter receptors and, 260-62
 - plasmacytoma immunoregulation and, 634
 - preparation of, 263-64
 - reovirus receptors and, 262-69
 - retrovirus receptors and, 269-71
 - vitamin receptors and, 257-60
- Antidiotype autoimmunity, 272-74
- Antiimmunoglobulin antibodies
 - B-cells and, 640-41
- Antilaminin
 - natural killer cells and, 654
- Antinitroiodophenylacetyl antibodies
 - idiotypes of, 156-57
- Antiphosphocholine antibodies
 - idiotypes of, 154-56
- Antitarget antibodies
 - natural killer cells and, 654
- Antitoxins
 - See specific type
- Antitransferrin receptor
 - natural killer cells and, 654
- Antitrypsin
 - biosynthesis of, 244-45
- Arachidonic acid pathway
 - complement component C5b-8 and, 520
- ARC
 - See Acquired immunodeficiency syndrome-related complex
- Ascites tumor cells
 - complement membrane attack complex and, 520
- Asialoglycoprotein
 - immunoglobulin A and, 402-4
- Astroglia
 - panspecific hemopoietin and, 209
- ATL
 - See Leukemias, adult T-cell
- ATP
 - See Adenosine triphosphate
- Autoantibodies
 - donor-T-cell proliferation and, 187-88
 - interleukin-2 and, 683
- Autoimmune disease

- antidiotypic antibodies and, 254, 272-74
- T-cell-replacing factor and, 186
- Autoimmune sera
 - antidiotypic antibodies in, 273
- Autoimmunity
 - antidiotypic, 272-74
 - controls in B-cell growth and, 26
 - idiotypic mimicry and, 271-74
 - muramyl dipeptides and, 379
- Avian leukosis virus, 320
- Avian retroviruses
 - oncogenic, 318-20
- Azathioprine
 - renal transplantation and, 135-36, 139
- p-Azophenylarsenate
 - antibodies against
 - idiotypes of, 157-59
- B**
- Bacillus Calmette-Guerin*
 - cancer immunotherapy and, 681
- Bacterial lipopolysaccharide
 - adjuvant activity of, 374-75
- Basophilic leukemia
 - immunoglobulin E receptor and, 420
- Basophils
 - immunoglobulin E receptor and, 457-58
- BCDF
 - See B-cell differentiation factors
- B-cell differentiation, 167-97, 529-30, 625-32
 - allelic exclusion and, 350-51
 - B-cell precursors in, 625-26
 - immunoglobulins and, 189-91, 339, 349-55, 626-32
 - interleukin-1 and, 168
 - major histocompatibility complex and, 189-97
 - model systems for, 341-42
 - pathway of, 350-55
 - T-cell-derived lymphokines and, 640
 - T-cell-replacing factors and, 184-88
- B-cell differentiation factors, 168-84
 - activated B-cells and, 171-72
 - carbohydrate moieties and, 181-84
 - hybridomas and, 172
 - murine, 177
 - receptors for, 177-81
- B-cell growth factors, 18-19
 - activity of, 171
 - c-myc* gene expression and, 327
 - hybridomas and, 171
 - muramyl dipeptides and, 379
 - resting B-cells and, 168
- B-cell maturation factors, 21, 174-75
- B-cell memory
 - immunological adjuvants and, 371
- B-cell proliferation factors
 - cell-derived, 17-19
 - T-cell-derived, 19-20
- B-cells, 8, 13-26
 - activated, 13-14
 - B-cell differentiation factors and, 171-72
 - cell-cycle control of, 25-26
 - interleukin-2 receptor and, 178-79
 - lymphokines and, 174
 - allograft rejection and, 134
 - antiimmunoglobulin antibodies and, 640-41
 - antitrypsin biosynthesis and, 244
 - class switching in, 631, 638-39
 - c-myc* gene expression and, 327
 - cognate interactions of, 167
 - complement component C3 and, 17-18
 - G0 to G1 transition in, 24
 - Ia expression on, 282
 - immune response and, 529
 - immune T-cell proliferation and, 189-91
 - immunoglobulin A and, 389-90
 - immunoglobulin synthesis and, 13
 - γ -interferon and, 172-74
 - interleukin-2 and, 172-74
 - interleukin-2 receptors on, 83-84
 - lymphokines and, 168
 - muramyl dipeptides and, 379
 - panspecific hemopoietin and, 217-20
 - pertussis toxin and, 375
 - responses of
 - alpha factors and, 17-18
 - initiation of, 14-15
 - interleukin-2 and, 20-21
 - resting, 22-24
 - anti-Ig and, 168-69
 - B-cell differentiation factor and, 174-77
 - T-helper cells and, 174
- self-Ia determinants and, 194-97
- T-helper cells and, 16-17, 167
- B-cell stimulatory factor p1
 - anti-IgM-activated B-cells and, 169
- B-cell tumor models, 621-42
- BCGF
 - See B-cell growth factors
- Blood
 - immunoglobulin A and, 389-93, 405
- Bone marrow transplantation
 - panspecific hemopoietin and, 223
- Bordetella pertussis* vaccine
 - adjuvant activity of, 375-76
- Brucella* spp.
 - muramyl dipeptides and, 378
- Burkitt's lymphoma
 - c-myc* genes and, 321-26
 - Epstein-Barr virus and, 322
- C**
- Calcium
 - cytoplasmic
 - T-cell antigen receptor and, 593
 - intracellular
 - immunoglobulin E receptor and, 451-58
 - T-cell activation and, 603-8
- Cancer
 - interleukin-2 and, 684
- Cancer immunotherapy, 681-705
 - interleukin-2 and, 689-94, 704-5
 - lymphokine-activated killer cells and, 704-5
- Carbohydrates
 - immunoglobulin E binding and, 428
 - lymphoid cells and, 181
- Carcinoma
 - c-myc* gene amplification and, 326
 - lymphokine-activated killer cells and, 702
- cDNA
 - interleukin-2 receptor, 72-75
 - T-cell activation and, 609-10
 - T-cell antigen receptor and, 594-95
 - T3 chains and, 597
- Cell-cell interactions
 - activated lymphocytes and, 16
- Cell-mediated immunity
 - allograft rejection and, 134-40
 - bacterial lipopolysaccharide and, 374

- immunological adjuvants and, 371
- muramyl dipeptides and, 378-79
- pertussis toxin and, 375
- Cell-mediated lympholysis
 - interleukin-2 and, 683
 - renal transplantation and, 139
- Cell membranes
 - complement and, 504-55
- Cell selection theory, 2-9
- Cellular oncogenes, 318
- Chloroquine
 - adult T-cell leukemia and, 90
- Cholera toxin
 - immunoglobulin A antibodies and, 406-7
- Choline phosphate
 - cytolysin inhibition and, 664-65
- Class switching
 - B-cells and, 631, 638-39
- CLL
 - See Leukemias, chronic lymphocytic
- Clonal selection theory, 7
- c-myc genes
 - alterations in, 320-26
 - B-cell tumors and, 640-41
 - expression of
 - regulation of, 327-30
 - protein of, 332-33
 - structure of, 318-20
- Coagulation pathway
 - proteases of
 - production of, 243
- Collagenase
 - muramyl dipeptides and, 379
- Colon carcinoma
 - cancer immunotherapy and, 705
 - c-myc gene amplification and, 326
- Colony-stimulating factor
 - muramyl dipeptides and, 379
- Complement
 - activation of
 - immunoglobulin A and, 407
 - cytolytic mechanism of, 503, 520-22
 - natural killer cells and, 657
 - proteins of, 503
- Complement biosynthesis, 231-45
 - pathways of, 232-34, 504
 - activators of, 235-45
 - aluminum hydroxide and, 371
- Complement cascade, 232-34
- Complement component C1
 - classical pathway and, 232-33
 - control protein of, 235
- Complement component C2
 - factor B and, 236-38
- Complement component C3
 - alternative pathway and, 233-34
 - B-cell activation and, 17-18
 - expression of, 238-41
 - immunoglobulin A and, 407
- Complement component C4
 - binding proteins of, 241-42
 - biosynthesis of, 240-41
- Complement component C5, 242
 - activation of, 503
 - properties of, 505-7
- Complement component C5b
 - properties of, 506
- Complement component C5b-7
 - membrane attack site and, 510-12
- Complement component C5b-8, 511-12
 - arachidonic acid pathway and, 520
- Complement component C5b-9
 - composition and structure of, 512-13
- Complement component C5 convertase, 503, 508-9
 - reaction sequence of, 509-10
- Complement component C6
 - properties of, 506-7
- Complement component C7
 - properties of, 506-7
- Complement component C8
 - properties of, 506-7
- Complement component C9
 - polymerization of, 505, 513-16
 - properties of, 506-8
- Complement component S-protein
 - properties of, 506-8
- Complement factor B
 - complement component C2 and, 236-38
- Complement factor Bb
 - plasminogen activation and, 243
- Complement factor D
 - alternative pathway activation and, 236
- Complement factor H, 241-42
- Complement factor H receptor
 - idiotypic mimicry of, 270
- Complement factor I, 241-42
- Complement membrane attack complex, 503-22
 - channels of, 518-20
 - control of, 516-18
 - lymphocytes and, 520-22
 - membrane-binding site of, 510-11
- precursor proteins of, 505-8
- Concanavalin A
 - immunoglobulin E aggregation and, 439
- lymphadenopathy-associated virus and, 102
- phospholipid methylation and, 443
- T-cell activation and, 602, 606
- urokinase expression and, 243
- Contact sensitivity
 - macrophages and, 52
 - passive transfer of, 39
 - T-acceptor cells and, 58-59
 - T-helper factors and, 48-49
 - T-suppressor factors and, 55-56
- Corynebacterium parvum*
 - cancer immunotherapy and, 681
- Cromolyn
 - immunoglobulin E-mediated secretion and, 454-56
- Cyclic AMP
 - immunoglobulin E receptor and, 445-46
 - natural killer cytotoxic factor and, 662-63
- Cycloheximide
 - interleukin-2 mRNA and, 613-14
 - interleukin-2 receptor and, 80-81
- Cyclophosphamide
 - adoptive immunotherapy and, 696, 703
 - alloantigens and, 683-84
 - T-acceptor cells and, 53
 - T-suppressor cells and, 59-60
- Cyclosporin
 - renal transplantation and, 135-36, 139
- Cyclosporin A
 - alloantigens and, 683-84
- Cytolysin
 - binding of, 664-66
 - cytotoxicity of, 653, 659-61
 - lymphotoxin and, 670
 - natural killer cytotoxic factor and, 663-64
 - target cell lysis and, 667-69
 - tumor necrosis factor and, 670
- Cytolytic T-cells
 - binding to target cells, 654
 - mechanism of, 520-22
 - murine MHC class-I molecules and, 485
- Cytomegalovirus
 - lymphadenopathy-associated virus and, 112

- Cytopathic effects
 lymphadenopathy-associated virus and, 104-6
- Cytotoxic T-cells, 529
- allograft rejection and, 122-28
- beta gene rearrangements in, 549
- interleukin-2 and, 684
- D**
- Deletion mutagenesis
 murine MHC products and, 489
- recombinant H-2 genes and, 483
- Dendritic cells
 allograft rejection and, 121-22
- Ia expression on, 282
- Dermatitis herpetiformis
 immunoglobulin A and, 407
- Detergents
 immunoglobulin E receptor and, 425
- Dextran
 antibodies against
 idiotypes of, 151-54
- monoclonal immunoglobulins and, 622
- Diabetes mellitus
 antiidiotypic antibodies and, 254, 272
- Diacylglycerol
 interleukin-2 receptor and, 81
- protein kinase C and, 608
- Differentiation factors
 See specific type
- Diphtheria antitoxin
 avidity of, 5
- Diphtheria toxin
 muramyl dipeptides and, 378
- Diphtheria toxoid
 liposomes and, 371-72
- muramyl dipeptides and, 378
- Diterpine forskolin
 B-cell growth and, 17
- DMGT
 See DNA-mediated gene transfer
- DNA-mediated gene transfer
 major histocompatibility complex and, 282-309
- recombinant H-2 genes and, 483
- DNA rearrangements
 immunoglobulin genes and, 545-52
- DNA sequencing
 class-I murine MHC and, 473-80
- DNA viruses
 lymphadenopathy-associated virus and, 112
- E**
- ELISA
 See Enzyme-linked immunosorbent assay
- Endocytosis
 immunoglobulin A receptor and, 401-2
- Endoglycosidase F
 interleukin-2 receptor protein and, 82
- Endotoxin
 complement component C3 and, 239
- Enzyme-linked immunosorbent assay
 lymphadenopathy-associated virus and, 107
- Eosinophils
 immunological adjuvants and, 371
- panspecific hemopoietin and, 208
- Epidermal growth factor
 c-myc gene expression and, 327-28
- Epinephrine
 antiidiotypes and, 148
- Epithelial cells
 complement synthesis in, 231, 235
- Ia expression on, 282
- Epitopes, 255-56, 302-5
 immunogenicity of
 enhancement of, 369
- Epstein-Barr virus
 acquired immunodeficiency syndrome and, 106
- B-cell responses and, 18
- Burkitt's lymphoma and, 322
- lymphadenopathy-associated virus and, 102, 112
- Erythrocytes
 complement membrane attack complex and, 516-18
- panspecific hemopoietin and, 208
- Erythroid cells
 panspecific hemopoietin and, 208, 214-15
- Erythropoiesis
 panspecific hemopoietin and, 215
- Erythropoietin, 215
- Exon-shuffling
 murine MHC products and, 489
- recombinant H-2 genes and, 483
- F**
- FCA
 See Freund's complete adjuvant
- Fetal cells
 immunoglobulin gene expression in, 553-55
- Fibroblast-activating factor
 muramyl dipeptides and, 379
- Fibroblasts
 c-myc gene expression and, 327-28
- complement component C3 in, 239
- complement synthesis in, 231, 235
- Foot-and-mouth disease virus
 muramyl dipeptides and, 378
- Franklin's disease, 623
- Freund's complete adjuvant, 376-80
- G**
- Galactan
 antibodies against
 idiotypes of, 156
- Gene cloning
 recombinant H-2 genes and, 483
- Genetic recombination
 class-I murine MHC and, 476-79
- Gene transfer
 class-I murine MHC and, 476-79
- See also DNA-mediated gene transfer
- Globulins
 antibody specificity and, 3
- See also specific type
- Glucocorticoids
 immunoglobulin secretion and, 641
- Glucocorticosteroids
 urokinase and, 243
- Glycosylation
 immunoglobulin secretion and, 641
- panspecific hemopoietin and, 211
- Graft rejection
 major histocompatibility complex and, 281
- murine, 471

- See also Allograft rejection
 Graft-versus-host disease
 donor-T-cell proliferation and,
 187-88
 panspecific hemopoietin and,
 222
 Graft-versus-host response
 T-cell-replacing factor and,
 186-88
 Granulocyte colony-stimulating
 factor
 panspecific hemopoietin and,
 208
 Graves' disease
 antiidiotypic antibodies and,
 254, 259, 272
 Growth factors
 See specific type
- H**
- Helper T-cells
 See T-helper cells
 Helper T-factors
 See T-helper factors
 Hemolysins, 4
 Hemopoietic cells
 murine leukemia virus and,
 208
 Hemopoietic progenitor cells
 panspecific hemopoietin and,
 214-15
 Hemopoietic stem cells
 panspecific hemopoietin and,
 216-17
 stimulation of, 206
 Hemopoietic system
 panspecific hemopoietin and,
 222
 Hemopoietin
 See Panspecific hemopoietin
 Hepatitis B surface antigen
 muramyl dipeptides and, 378
 Hepatitis B virus
 lymphadenopathy-associated
 virus and, 112
 Hepatocytes
 complement component C3
 gene expression in, 239
 complement component C5
 synthesis in, 242
 complement gene expression
 in, 232
 immunoglobulin A transport
 and, 394-95
 Hepatoma
 complement synthesis in, 231,
 235
 Herpes simplex type I
 muramyl dipeptides and, 378
 Herpes simplex virus
 interleukin-2 and, 688
- HLA
 See Human leukocyte antigen
 Hormone receptors
 idiotypic determinants of, 148
 idiotypic mimicry of, 257-60
 HTLV-I
 See Human T-lymphotropic
 virus-I
 HTLV-III
 See Human T-lymphotropic
 virus-III
 Human leukocyte antigen, 473
 allograft rejection and, 132-33
 class-I variants of, 478-84
 Human T-lymphotropic virus-I
 acquired immunodeficiency
 syndrome and, 99
 adult T-cell leukemia and, 86-
 89
 Human T-lymphotropic virus-
 III
 acquired immunodeficiency
 syndrome and, 99
 Humoral immunity
 allograft rejection and, 132-34
 antigen-specific B-cells and,
 13
 immunoglobulin A and, 398
 immunological adjuvants and,
 371
 liposomes and, 372
 muramyl dipeptides and, 378
 Hybridoma proteins
 antidextran
 amino acid sequence anal-
 ysis of, 152-54
 Hybridoma
 B-cell differentiation factors
 and, 172
 B-cell growth factors and, 18-
 19, 171
 immunoregulation of, 634
 lymphokines and, 21-22
 monoclonal antibodies and,
 622
 20- α -Hydroxysteroid de-
 hydrogenase
 T-cell differentiation and, 209-
 10
 Hyperbilirubinemia
 interleukin-2 therapy and, 694
 Hypersensitivity
 antibodies and, 4
 delayed-type
 allograft rejection and, 122-
 25
 antigen-specific transfer fac-
 tors and, 9
 immunological adjuvants
 and, 371
 muramyl dipeptides and,
 378-79
- pertussis toxin and, 376
 T-acceptor cells and, 53
 transfer of, 4
 T-cell activation and, 612-13
- I**
- Ia**
 antibody and T-cell recogni-
 tion of, 301-8
 bacterial lipopolysaccharide
 and, 374
 expression of, 282, 293-97
 Ia-transfectants
 antigen-presenting cell func-
 tion of, 297-301
 Idiotoxes, 147-60, 254
 antibodies and, 151-57
 immunoglobulins and, 147-49
 localization of
 peptides and, 159-60
 location of, 255
 nature of, 149-51
 structural correlates of, 151-59
 Idiotypes
 antigen receptors and, 254
 plasmacytoma immunoregula-
 tion and, 634-36
 Idiotypic mimicry, 253-75
 autoimmunity and, 271-74
 hormone receptors and, 257-
 60
 leukocyte receptors and, 270
 neurotransmitter receptors and,
 260-62
 receptor function and, 257-69
 retrovirus receptors and, 269-
 71
 virus receptors and, 262-69
 vitamin receptors and, 257-60
 Immune complex disease
 donor-T-cell proliferation and,
 187-88
 Immune complexes
 clearance of
 secretory component and,
 405
 hepatobiliary immunoglobulin
 A pathway and, 395-98
 Immune deficiency
 plasmacytoma-induced mac-
 rophage activation and,
 637
 Immune function
 immunoglobulin-secreting
 tumor cells and, 632-38
 Immune hemolysis, 504
 Immune response
 antiidiotypes in, 254
 lymphocytes and, 6
 pertussis toxin and, 375

- Immune response gene defects, 576-79
- Immune system
K-, D-, and L-gene products and, 472
panspecific hemopoietin and, 222
- Immunity
antidiotopes and, 148
interleukin-2 and, 57-58
side-chain theory of, 2
See also Cell-mediated immunity, Humoral immunity
- Immunoblotting
lymphadenopathy-associated virus and, 107
- Immunocytoma
immunoglobulin E receptor and, 420
- Immunodeficiency
controls in B-cell growth and, 26
- Immunofluorescence, 4
dendritic cells and, 121
lymphadenopathy-associated virus and, 107
- Immunoglobulin A, 389-410
antibody-mediated cytotoxicity and, 407-8
antigen clearance and, 405
function of, 405-9
hepatobiliary pathway of, 394-98
immune protection and, 405-9
liver and, 404
role in blood, 389-93, 405
secretion of
 tunicamycin and, 641
 structure of, 391-93
 synthesis of, 389-93
 transport of, 393-404
Immunoglobulin A receptor
endocytosis of, 401-2
secretory component and, 398-401
- Immunoglobulin E
binding sites on, 427-30
secretion of
 tunicamycin and, 641
- Immunoglobulin E receptor, 419-60
adenylate cyclase and, 445-46
aggregation of, 430-35
binding to, 426-30
detergents and, 425
intracellular calcium and, 451-58
lipids and, 425-26
methyltransferases and, 440-45
mobility of, 435-37
phosphatidyl inositides and, 446-51
plasma membrane and, 435
proteases and, 439-40
purification of, 421
structure of, 421-26
topology of, 424
- Immunoglobulin G
classical complement pathway and, 232-33
- Immunoglobulin genes
amino acid sequence analysis and, 624
B-cell differentiation and, 626-32
B-cell tumors and, 622-23
chromosomal locations of, 532-33
combinatorial joining in, 560
constant regions of, 541-42
diversity in, 558-66
 germline, 558-60
 diversity segments of, 538-40
expression of
 B-cell precursors and, 628-32
 joining segments of, 540-41
 organization of, 533-36
 rearrangements of, 545-58
 allelic exclusion and, 548-49
 B-cell precursors and, 627-28
 mechanisms of, 546-48
 ordered, 553-56
 site of, 556-58
 tissue-specific, 545-46
 somatic mutations in, 560-63
 structure of, 531-32, 626-27
 superfamily of, 542-43
 genealogic tree for, 543-45
 homology unit of, 543
T-cell receptor genes and, 568-71
variable-region, 339-63
 assembly of, 343-46, 357-63
 expression of, 346-49
 organization of, 342-43
 regulation of, 349-55
 variable segments of, 536-38
- Immunoglobulin M
B-cell tumors and, 640
classical complement pathway and, 232-33
- Immunoglobulins, 8
antigen-specific transfer factor and, 9
B-cell differentiation and, 189-91
crosslinking on B-cells, 23
determinants on lymphocytes, 7
idiotype and, 147-49
immune response and, 529
immunological adjuvants and, 371
lymphokines and, 170
monoclonal, 621-22
synthesis of
 B-cells and, 13
- Immunological adjuvants, 369-83
 bacterial, 373-80
 nonbacterial, 370-73
- Immunological agnosis
T-suppressor cells and, 38
- Immunological memory
negative, 6-7
- Immunological tolerance
self-marker theory of, 4
- Immunopotential, 369, 380-82
- Immunosuppression
anti-interleukin-2-receptor antibodies and, 90-91
renal transplantation and, 135-36, 139
- Immunotherapy
adoptive
 interleukin-2 and, 694-705
 cancer, 681-705
 interleukin-2 and, 689-94, 704-5
 lymphokine-activated killer cells and, 704-5
- Immunotoxins
adult T-cell leukemia and, 90
- Indomethacin
interleukin-2 toxicity and, 694
- Influenza
muramyl dipeptides and, 378
- Influenza virus
immunoglobulin A antibodies and, 406
- Inositol triphosphate
T-cell antigen receptor and, 593
- Insulin
antidiotopes and, 148
c-myc gene expression and, 327
- Insulin receptors
idiotypic mimicry of, 258-59
- Interferon
natural killer cytotoxic factor and, 662
- α -Interferon
c-myc gene regulation and, 329-30
natural killer cell activity and, 668

- β -Interferon**
c-myc gene regulation and, 329-30
- γ -Interferon**
 activated B-cells and, 172-74
 B-cell maturation and, 21
 complement component C2 and, 237-38
 complement component C3 and, 239
 interleukin-2 therapy and, 691
 natural killer cell activity and, 668
 panspecific hemopoietin and, 208
 T-cell activation and, 609-15
- Interleukin-1**
 adjuvant activity of, 381
 bacterial lipopolysaccharide and, 374
 B-cell differentiation and, 168
 B-cell stimulation and, 18
 complement component C2 and, 237-38
 complement component C3 and, 239
 lymphocyte-activating factor and, 381
 muramyl dipeptides and, 379-80
 T-cell activation and, 602, 609
- Interleukin-2**
 acquired immunodeficiency syndrome and, 98
 activated B-cells and, 172-74
 adjuvant activity of, 381
 adoptive immunotherapy and, 694-705
 B-cell growth factors and, 19
 B-cell responses and, 20-21
 cancer immunotherapy and, 689-94, 704-5
c-myc gene expression and, 327
 immunity and, 57-58
 panspecific hemopoietin and, 208
 pharmacologic role of, 682-85
 production of
 suppressor factors and, 39
 T-cell activation and, 602, 609-15
 T-cell-replacing factor and, 173
 T-suppressor factors and, 56-57
 toxicity of, 692-94
- Interleukin-2 receptor**, 69-91
 activated B-cells and, 178-79
 adult T-cell leukemia and, 86-89
 amino acid sequence of, 82
- B-cells and, 83-84
 cDNAs of
 cloning of, 72-75
 gene expression of, 78-80
 genomic structure of, 75-76
 high and low affinity, 84-86
 monoclonal antibodies and, 70-72
 mRNAs of, 76-78
 protein of
 posttranslational processing of, 81-83
 purification of, 72-75
 reexpression of, 80-81
 T-cell activation and, 79-80
 thymocytes and, 83-84
- Interleukin-3**
 assay for, 209-10
 mast-cell growth factors and, 211
 T-cells and, 210, 217-19
 See also Panspecific hemopoietin
- Ionomycin**
 T-cell activation and, 604-6
- Isotypes**
 plasmacytoma immunoregulation and, 637-38
- Isotype switching**
 B-cell tumors and, 639
- K**
- Kaposi's sarcoma**
 acquired immunodeficiency syndrome and, 98
- Keratinocytes**
 panspecific hemopoietin and, 209
- Killer cells**, 8
 cytolytic mechanism of, 520-22
 lymphokine-activated, 697-69
 cancer immunotherapy and, 704-5
 See also Natural killer cells
- Kuhn's paradigm theory**, 1
- L**
- α -Lactalbumin**
 protective effects of, 406
- Lactoferrin**
 protective effects of, 406
- Large granular lymphocytes**
 cytotoxicity of, 653, 659-61
 natural killer cells and, 651
 target cell lysis and, 667-69
- Lectins**
 T-cell activation and, 602, 606
- Leprosy**
 interleukin-2 and, 684
- Leukemias**
 acute lymphocytic
 B-cell precursors in, 625
 adult T-cell
 anti-interleukin-2-receptor antibodies and, 89-90
 interleukin-2 receptor and, 86-89
 basophilic
 immunoglobulin E receptor and, 420
c-myc gene amplification and, 326
 chronic lymphocytic
 B-cell differentiation in, 639-40
 immunoregulation of, 639-41
 isotype switching in, 639
 myelomonocytic
 panspecific hemopoietin and, 205-6, 210-11
 panspecific hemopoietin and, 205-6, 210-11, 223-25
 promyelocytic
 c-myc gene amplification and, 326
- Leukemogenesis**
 panspecific hemopoietin and, 206, 223-25
- Leukocyte migration test**
 renal transplantation and, 139
- Leukocyte receptors**
 idiotypic mimicry of, 270
- Leukocytes**
 passenger
 allograft rejection and, 121
 polymorphonuclear
 complement membrane attack complex and, 520
- Leukoregulin**
 natural killer cytotoxic factor and, 672
- Leukotriene B4**
 complement component C5b-8 and, 520
- Leukotrienes**
 immunoglobulin E receptor and, 419
- Levamisole**
 cancer immunotherapy and, 681
- Levans**
 monoclonal immunoglobulins and, 622
- Ligands**
 monoclonal immunoglobulins and, 622
- Lipid A**
 adjuvant activity of, 374-75
 B-cell responses to, 14
 complement component C3 and, 239

- Lipid bilayers
complement and, 504
cytolysin and, 664-66
- Lipids
complement membrane attack complex and, 518-19
immunoglobulin E receptor and, 419, 425-26
- Lipopolysaccharides
B-cell responses to, 14, 23
bacterial
adjuvant activity of, 374-75
- Lipoproteins
B-cell responses to, 14
- Liposomes
adjuvant activity of, 371-73
cytolysin inhibition and, 665
humoral immunity and, 372
- Liver
complement synthesis in, 231
immunoglobulin A-producing cells in, 404
- Local inflammatory response
immunological adjuvants and, 371
- LT
See Lymphotoxin
- Lymphadenopathy-associated virus
acquired immunodeficiency syndrome and, 97-112
antibody assays for, 107
cell receptors for, 104
characteristics of, 99-102
continuous cell lines for, 106-7
cytopathic effects of, 104-5
genome of, 100-2
isolation of, 99
markers of, 107-9
morphology of, 100
proteins of, 100
replication of, 102
sero-epidemiological data and, 107-8
seropositivity and, 108-9
T-helper cells and, 103-4
- Lymphadenopathy syndrome, 98
- Lymph nodes
allograft rejection and, 128-29
- Lymphocyte-activating factor
interleukin-1 and, 381
murabutide and, 380
- Lymphocytes
activation of
cell-cycle control of, 16
lymphadenopathy-associated virus and, 102
bacterial lipopolysaccharide and, 374
cytolytic mechanism of, 503, 520-22
immunoglobulin A receptors on, 407
immunoglobulin determinants on, 7
immunological adjuvants and, 370
muramyl dipeptides and, 379
radiosensitivity of, 6
See also B-cells, Large granular lymphocytes, T-cells
- Lymphokine-activated killer cells, 697-99
cancer immunotherapy and, 704-5
- Lymphokines
A-cells and, 16, 22
acquired immunodeficiency syndrome and, 98
activated lymphocytes and, 16
adjuvant activity of, 380-81
B-cells and, 168, 174
carbohydrate residues on, 181
cellular sources of, 21-22
immunoglobulins and, 170
panspecific hemopoietin and, 208
production of, 16
T-cell activation and, 608
T-cell antibodies and, 594
T-cell-derived
B-cell differentiation and, 640
T-cells and, 16, 21-22, 169, 593
urokinase and, 243
- Lympholysis
cell-mediated
interleukin-2 and, 683
renal transplantation and, 139
- Lymphomas
B-cell precursors in, 625
cells
urokinase and, 242-43
c-myc genes in, 320-21
immunoregulation of, 639-41
isotype switching in, 639
See also Burkitt's lymphoma
- Lymphopoiesis
panspecific hemopoietin and, 217
- Lymphotoxin
cytolysin and, 670
natural killer cytotoxic factor and, 669-72
- Lysolipids
cytolysin inhibition and, 665
- Lysozyme
protective effects of, 406
- M
Macroglobulin
biosynthesis of, 245
Macrophage colony-stimulating factor
panspecific hemopoietin and, 208-9
Macrophage-inhibiting factor
muramyl dipeptides and, 379
Macrophages
as acceptor cells, 52
allograft rejection and, 134-36
antitrypsin biosynthesis and, 244
B-cell growth and, 26
complement gene expression in, 232
complement membrane attack complex and, 520
complement synthesis in, 231
contact sensitivity and, 52
cytotoxicity of
mechanism of, 674-75
Ia expression on, 282
immunoglobulin A receptors on, 407
immunological adjuvants and, 370
murabutide and, 380
murameteide and, 380
muramyl dipeptides and, 379
natural killer cells and, 651
panspecific hemopoietin and, 208, 214-15
plasmacytoma cells and, 637
procoagulant activity of, 243-44
T-cell activation and, 602
Major histocompatibility complex
allograft rejection and, 120
antigens
inducibility on allografts, 125
T-cells and, 602
B-cell differentiation and, 189-97
gene expression of, 288-97
gene transfer, 281-309
organization of, 283-85
proteins and genes of, 282-83
structure-function analysis of, 297-308
T cell-A cell-B cell interactions and, 15
T-cell antigen receptor and, 566-79
T-cell antigen recognition and, 529
T-helper cells and, 167
T-helper factors and, 44
See also Murine MHC class-I mutants
Malignancy
controls in B-cell growth and, 26

- See also specific type
- Mammalian reovirus receptors
idiotypic mimicry of, 262-69
- Mannose
natural killer cytotoxic factor
and, 663
- Mast-cell growth factors
interleukin-3 and, 211
- Mast cells
immunoglobulin E receptor
and, 457
panspecific hemopoietin and,
206-9, 214-15
- Maturation factors
See specific type
- Megakaryocyte colony-
stimulating factor
panspecific hemopoietin and,
215
- Megakaryocytes
panspecific hemopoietin and,
206-8, 214-15
- Meiotic recombination
class-I murine MHC and, 478-
79
- Melanoma
cancer immunotherapy and,
705
interleukin-2 and, 694
- Methanol-extracted residue
cancer immunotherapy and,
681
- Methyltransferases
immunoglobulin E receptor
and, 440-45
- MHC
See Major histocompatibility
complex
- Mitogens
B-cell growth factors and, 19
lymphadenopathy-associated
virus and, 102
- Mitotic recombination
class-I murine MHC and, 478-
79
- Mixed colony-stimulating factor
panspecific hemopoietin and,
215
- Mixed leukocyte reaction
passenger leukocytes and, 121
- Mixed lymphocyte culture
renal transplantation and, 139
- Monensin
adult T-cell leukemia and, 90
interleukin-2 receptor protein
and, 83
natural killer cytotoxic factor
and, 662-63
- Monoclonal antibodies, 1, 8,
621-23
allograft rejection and, 135
anti-interleukin-2 receptor and,
70-72
B-cell precursors and, 625-26
- B-cell responses and, 17-23
class-I murine MHC and, 481-
83, 489-94
complement component C9
and, 519
immunoglobulin A, 407
immunoglobulin E receptor
and, 429-30
T-cell activation and, 603-5
T-cell antigen receptor and,
533, 594
T3 chains and, 596-97
- Monoclonal antidiotopes, 150
- Monoclonal immunoglobulins,
621-22
- Monocytes
antitrypsin biosynthesis and,
244
complement synthesis in, 231,
235
Ia expression on, 282
macroglobulin synthesis and,
245
plasminogen activation and,
242-43
procoagulant activity of, 243-
44
urokinase-binding sites of, 243
urokinase synthesis in, 242-43
- Monokines
adjuvant activity of, 380-81
bacterial lipopolysaccharide
and, 374
- mRNA
interleukin-2 receptor, 76-78
adult T-cell leukemia and,
88-89
- Mucins
protective effects of, 406
- Murabutide
adjuvant activity of, 380
- Murametide
adjuvant activity of, 380
- Muramyl dipeptides
adjuvant activity of, 376-80
- Murine leukemia virus
hemopoietic cells and, 208
interleukin-3 and, 218
vire-B phenotype of, 625
- Murine MHC class-I mutants,
471-96
conservation of sequence in,
480
diversity of sequence in, 479-
80
genetic recombination in, 476-
79
in vitro, 481-85
analysis of, 488-89
in vivo, 473-80
cellular recognition of, 485-
88
recombinant H-2 genes and,
483-84
- regulatory, 484-85
somatic cell, 481-83
structural analysis of, 473-76
structure-function studies of,
485-94
- Mutagenesis
recombinant H-2 genes and,
483
- Mutants
See specific type
- Myasthenia gravis
antiidiotypic antibodies and,
254, 262, 272
- Myeloid cells
panspecific hemopoietin and,
207, 210-11, 214-15
- Myeloma proteins
antibodies and, 621-22
- Myelomas
immunoglobulin genes in, 627
isotype switching in, 639
- Myelomonocytic leukemia
panspecific hemopoietin and,
205-6, 210-11
- N
- Natural cytotoxic cells
tumor necrosis factor and,
672-74
- Natural killer cells, 651-75
activation of, 658
allograft rejection and, 134-36
beta gene rearrangements in,
550
binding to target cells, 654-58
cytolytic mechanism of, 520-
22
cytotoxic molecules of, 658-
64
binding of, 664-67
target cell lysis and, 667-69
- Natural killer cytotoxic factor,
653, 661-64
binding of, 666-67
leukoregulin and, 672
lymphotoxin and, 669-72
tumor necrosis factor and,
669-72
- Natural selection theory, 7-8
- NC cells
See Natural cytotoxic cells
- Neoplastic cells
c-myc genes and, 327-30
- Neurotransmitter receptors
idiotypic mimicry of, 260-62
- Neutrophil-formyl-peptide recep-
tors
idiotypic mimicry of, 270
- Neutrophils
immunoglobulin A receptors
on, 407
panspecific hemopoietin and,
208, 214-15

- Nezeloff's syndrome
interleukin-2 and, 684
- 4-hydroxy-3-Nitro-5-iodophenylacetyl antibodies against
 idiotypes of, 156-57
- 2,4-di-Nitrophenyl monoclonal immunoglobulins and, 622
- NKCF
 See Natural killer cytotoxic factor
- Northern blot analysis
 T-cell antigen receptor and, 600
- O
- Oil emulsions
 adjuvant activity of, 377
- Oncogenes, 317-18
 c-myc
 alterations in, 320-26
 regulation of, 327-30
 structure of, 318-20
 cellular, 318
 v-myc
 structure of, 318-20
- Oncogenesis
 panspecific hemopoietin and, 223-25
- P
- Panspecific hemopoietin, 205-25
 analogues of, 213-14
 assays for, 206-10
 B-cells and, 217-20
 bioactivities of, 214-17
 hemopoietic progenitor cells and, 214-15
 hemopoietic stem cells and, 216-17
 metabolic effects of, 221
 molecular characterization of, 210-14
 nonspecific cytotoxicity of, 219
 oncogenesis and, 223-25
 physiology of, 221-22
 recombinant DNA studies and, 212
 structure of, 212-13
 T-cells and, 217-19
 Thy-1-inducing activity of, 215-16
 thymocytes and, 217
- Panspecific hemopoietin receptor, 220-21
 antibodies to, 221
- P-cells
 panspecific hemopoietin and, 206-7
- Peptides
 idiotope localization and, 159-60
- Peripheral sensitization
 allograft rejection and, 128-29
- Peroxidase
 protective effects of, 406
- Persisting cells
 See P-cells
- Pertussis toxin
 adjuvant activity of, 375-76
 immunoglobulin E and, 449
- Peyer's patches
 immunoglobulin A and, 390
- Phagocytes
 mononuclear
 complement component C2 synthesis in, 236-37
 complement synthesis in, 235
 factor D synthesis in, 235
 plasma neuron activation and, 242-43
- Phagocytosis
 muramyl dipeptides and, 379
 panspecific hemopoietin and, 214-15
- Phorbol esters
 B-cells and, 19, 23
 interleukin-2 receptor and, 81
- Phorbol myristate acetate
 interleukin-2 receptor and, 78-81
 urokinase and, 243
- Phosphate esters
 cytolysin inhibition and, 664-65
- Phosphatidyl inositides
 immunoglobulin E receptor and, 446-51
- Phosphocholine
 antibodies against
 idiotypes of, 154-56
- Phospholipase C
 immunoglobulin E receptor and, 447-49
 interleukin-2 receptor and, 81
- Phospholipids
 complement membrane attack complex and, 518-19
 cytolysin inhibition and, 665
 methylation of, 443-45
- Phosphorylation
 interleukin-2 receptor protein and, 83
- Phosphorylcholine
 monoclonal immunoglobulins and, 622
- Phytohemagglutinin
 interleukin-2 receptor and, 78-81
 lymphadenopathy-associated virus and, 102
- T-cell activation and, 602-5, 612-13
- Picryl chloride
 antigen-specific T-helper factors and, 43
- Plasma cells
 antibody production in, 4
- Plasmacytomas
 c-myc genes in, 321-25
 immunoglobulin genes in, 627
 immunoglobulin secretion and, 641
 immunoregulation of, 632-38
 antigen-specific, 636-37
 idiotype-specific, 634-36
 isotype-specific, 637-38
- Plasma membrane
 immunoglobulin E receptor and, 435
- Plasminogen
 activators of, 242-43
- Plasmodium knowlesi* circumsporozoite protein
 muramyl dipeptides and, 378
- Polyclonal antibodies
 B-cell responses and, 17
- Polymers
 adjuvant activity of, 373
- Polymorphonuclear leukocytes
 complement membrane attack complex and, 520
- Polymyxin B
 lipid A and, 374
- Prealbumin
 retinol-binding protein and, 258
- Precipitins, 4
- Prednisolone
 renal transplantation and, 135-36, 139
- Progesterone
 20- α -hydroxysteroid dehydrogenase and, 209
- Proliferation factors
 See specific type
- Promyelocytic leukemia
 c-myc gene amplification and, 326
- Prostaglandins
 muramyl dipeptides and, 379
 natural killer cytotoxic factor and, 662-63
- Proteases
 coagulation pathway, 243-44
 immunoglobulin E receptor and, 439-40
- Protein kinase C
 diacylglycerol and, 608
 interleukin-2 receptor and, 81
- Protein kinases
 immunoglobulin E receptor and, 456-57
- Protein sequencing

- class-I murine MHC and, 492-93
- Proto-oncogenes, 318
- Pseudomonas* toxoid
- muramyl dipeptides and, 378
- PSH
- See Panspecific hemopoietin
- R
- Radiation
- antibody formation and, 4-5
- Radiation leukemia virus
- T-suppressor factors and, 49
- Radioimmunoprecipitation assay
- lymphadenopathy-associated virus and, 107
- Receptors
- See specific type
- Recombinant DNA
- panspecific hemopoietin and, 212
- Reducing agents
- natural killer cytotoxic factor and, 661
- Related epitopes, 255
- Renal cell cancer
- cancer immunotherapy and, 705
- Renal transplantation
- immunosuppression and, 135-36, 139
- Reovirus receptors
- beta-adrenergic receptors and, 266-67
- idiotypic mimicry of, 262-69
- isolation of, 264-66
- Respiratory distress syndrome
- interleukin-2 therapy and, 694
- Reticuloendothelial system
- antigen uptake by, 16
- Retinol-binding protein receptors
- idiotypic mimicry of, 257-58
- Retroviruses
- acquired immunodeficiency syndrome and, 99
- acute transforming, 317-18
- avian
- oncogenic, 318-20
- Retrovirus receptors
- idiotypic mimicry of, 269-71
- Rheumatoid arthritis
- interleukin-2 and, 684
- RIPA
- See Radioimmunoprecipitation assay
- RNA sequencing
- class-I murine MHC and, 473-80
- S
- Salmonella typhimurium*
- bacterial lipopolysaccharide and, 374-75
- Saponin
- adjuvant activity of, 370
- Sarcomas
- adoptive immunotherapy and, 695
- lymphokine-activated killer cells and, 701-2
- Scientific concepts
- acceptance of, 1-2
- Secretory component
- immune complex clearance and, 405
- immunoglobulin A transport receptor and, 398-401
- Sialic acid
- natural killer cytotoxic factor and, 661
- Side-chain theory, 2, 46
- Skeleton demineralization
- plasmacytoma-induced osteoclast activation and, 637
- Slow-wave-sleep factor
- muramyl dipeptides and, 379
- Small cell lung carcinoma
- c-myc* gene amplification and, 326
- Sodium periodate
- natural killer cytotoxic factor and, 661
- Somatic hypermutation
- immunoglobulin genes and, 562-63
- T-cell antigen receptor and, 564-66
- Somatic mutation
- immunoglobulin genes and, 560-63
- Somatomedins
- c-myc* gene expression and, 327
- Southern blot analysis
- immunoglobulin genes and, 548-49
- T3 chains and, 597
- Stem cells
- hemopoietic
- panspecific hemopoietin and, 216-17
- stimulation of, 206
- Streptococcal M-type 24 protein
- muramyl dipeptides and, 378
- Strontium chloride
- natural killer cytotoxic factor and, 662-63
- Sulfation
- interleukin-2 receptor protein and, 83
- Suppressor T-cells
- See T-suppressor cells
- Suppressor T-factors
- See T-suppressor factors
- T
- T-acceptor cells, 52-55
- contact sensitivity and, 58-59
- crosslinking and, 54-55
- I-J and, 53-55
- properties of, 52-53
- Tanned erythrocyte electrophoretic mobility test
- renal transplantation and, 139
- T-cell activation, 593-615
- cell-surface molecules in, 593-96
- interleukin-2 receptor and, 79-80
- intracellular calcium and, 603-8
- molecular events in, 609-15
- T-cell antigen receptor and, 602-3
- T3 and, 596-608
- two-signal model for, 608-15
- T-cell antigen receptor, 529-79
- diversity in, 558-66
- heterodimer of, 593-96
- T3 and, 598-601
- major histocompatibility complex and, 566-79
- rearrangement and expression of, 553-58
- somatic hypermutation in, 564-66
- structure and organization of, 531-42
- T-cell activation and, 594, 602-3
- triggering of, 593
- See also Immunoglobulin genes
- T-cell differentiation
- 20- α -hydroxysteroid dehydrogenase and, 209-10
- interleukin-3 and, 210
- T-cell factors
- antigen-specific
- mode of action of, 47-49
- secreted
- T-cell receptors and, 46-47
- See also specific type
- T-cell growth factors
- See Interleukin-2
- T-cell receptors
- antigen-specific transfer factor and, 9
- class-I murine MHC and, 492-94
- idiotypic determinants of, 148
- isotypes of, 552
- secreted T-cell factors and, 46-47
- T-cell-replacing factors
- B-cell differentiation and, 184-88
- B-cell triggering and, 169

- interleukin-2 and, 173
- T-cells, 8
- A-cells and, 299-301
- acquired immunodeficiency syndrome and, 98-99
- allograft rejection and, 134-36
- antitrypsin biosynthesis and, 244
- B-cell growth factors and, 19
- B-cell responses to antigens and, 14-16
- c-myc* gene expression and, 327
- cytotoxicity of
- mechanism of, 674-75
- factor production of, 189-81
- hemopoietic stem cells and, 206
- Ia and, 301-8
- Ia expression on, 282
- immune response and, 529
- immunoglobulin A and, 390
- immunoglobulin gene expression in, 553-55
- interleukin-2 and, 684-85
- interleukin-3 and, 217-19
- lymphokines and, 16, 21-22
- monocyte procoagulant activity and, 243
- natural killer cells and, 651
- panspecific hemopoietin and, 210-11, 217-19
- pertussis toxin and, 375
- self-Ia determinants and, 194
- specificity of, 573-75
- development of, 575-76
- See also specific type
- T-cell tumors
- beta gene rearrangements in, 549
- Tetanus toxoid
- murabutide and, 380
 - muramyl dipeptides and, 378
- T-helper cells, 1, 8, 529
- A-cells and, 167
- allograft rejection and, 124
- B-cells and, 16-17, 26, 167
- beta gene rearrangements in, 549
- dendritic cells and, 122
- interleukin-2 and, 683
- lymphadenopathy-associated virus and, 103-4
- major histocompatibility complex and, 167
- monocyte procoagulant activity and, 243
- muramyl dipeptides and, 379
- plasmacytoma cells and, 636
- resting B-cells and, 174
- T cell-B cell interactions and, 189
- T-helper factors
- antigen-specific chains of, 45-46
 - structure of, 44-45
 - production of, 43
- B-cells and, 168
- chronic lymphocytic leukemia cells and, 639-40
- contact sensitivity and, 48-49
- I-A determinants of, 44, 47-48
- minimal model for, 43-45
- Thymectomy
- T-acceptor cells and, 53
 - T-suppressor cells and, 59-60
- Thymocytes
- immunoglobulin gene expression in, 555-56
 - interleukin-2 receptors on, 83-84
 - muramyl dipeptides and, 379
 - panspecific hemopoietin and, 217
- Thymus
- T-cells and, 529-30
- Thyrotropin receptors
- idiotypic mimicry of, 259-60
- Tissue thromboplastin
- monocyte procoagulant activity and, 243-44
- TNF
- See Tumor necrosis factor
- Tobacco mosaic virus
- anti-idiotypes of, 255-56
- Transfer factors
- antigen-specific, 9
 - See also specific type
- Transplantation antigens, 471
- class-I, 472
 - myeloma protein antigens and, 633
- Transplantation genes, 471-76
- TRF
- See T-cell-replacing factors
- Trypanosoma brucei*
- muramyl dipeptides and, 378
- Trypsin
- natural killer cells and, 655-56
 - natural killer cytotoxic factor and, 661
- T-suppressor cells, 1, 8, 37-62, 529
- adherence to antigen-coated plates, 44
 - afferent, 40, 59-60
 - antigen-specific, 9
 - beta gene rearrangements in, 550
 - biological function of, 60-62
 - plasmacytoma cells and, 636
- T-suppressor factors, 9
- antigen-specific, 49-51
 - disulfide-bonded structure of, 44-45
 - molecular forms of, 49-51
 - single-chain, 45
 - contact sensitivity and, 58-59
 - I-determinants of, 44, 47-51
 - mode of action of, 38-40
 - molecular biology of, 49
 - nonspecific
 - contact sensitivity and, 55-56
 - interleukin-2 and, 56-57
- Tuberculin
- delayed-type hypersensitivity and, 124
- Tumor cells
- immunoglobulin-secreting
 - immune function and, 632-38
- Tumorigenicity
- c-myc* gene amplification and, 326
- Tumor necrosis factor
- cytolysin and, 670
 - natural cytotoxic cells and, 672-74
 - natural killer cytotoxic factor and, 669-72
- Tumors
- B-cell growth factors and, 19
 - beta gene rearrangements in, 549
 - c-myc* gene alterations in, 320-26
 - complement synthesis and, 231
 - lymphokines and, 21-22
- Tunicamycin
- immunoglobulin secretion and, 641
 - natural killer cells and, 654
 - natural killer cytotoxic factor and, 666
 - tumor necrosis factor and, 670
- U
- Urokinase
- synthesis of, 242-43
- V
- Vibrio cholerae*
- immunoglobulin A and, 407-8
- Viruses
- immunoglobulin A antibodies and, 406
 - See also specific type
- Virus receptors
- idiotypic determinants of, 148
 - idiotypic mimicry of, 262-69
- Virus restriction assays
- murine MHC class-I mutants and, 486-88
- Vitamin receptors
- idiotypic mimicry of, 257-60
- v-myc* genes
- structure of, 318-20